Business Context and Reporting Period
This Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. on October 28, 2024. The filing serves as a Regulation FD disclosure regarding an upcoming investor presentation by CEO Dr. Anatoly Dritschilo at the ThinkEquity Conference on October 30, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on corporate events and does not contain financial statements or quantitative performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary update is the announcement of the CEO's presentation schedule and the availability of an updated corporate investor presentation.
Outlook, Commentary, and Risks
- Management Commentary: The CEO will provide updates on the Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment. Additionally, updates will be provided on Shuttle Diagnostics, Inc., focusing on predictive biomarkers for prostate cancer outcomes and a novel PSMA ligand for theranostic applications.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future results, strategy, and plans. These are subject to risks and uncertainties that may cause actual results to differ materially.
- Event Details: The presentation will be webcast and available for replay on the company's website.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) and the updated Investor Presentation (Exhibit 99.2) attached to the filing.
- Confirm the webcast link and replay availability for the October 30, 2024, ThinkEquity Conference presentation.
- Review the company's periodic reports (10-K/10-Q) for actual financial data, as this 8-K contains no financial metrics.
- Monitor the progress of the Phase 2 clinical trial for Ropidoxuridine as discussed in the upcoming presentation.